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Abstract. Stable solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs)
formulations to enhance the dissolution rates of poorly soluble drug spironolactone (SP)
were being developed. Probe ultra-sonication method was used to prepare SLNs and NLCs.
All NLCs contained stearic acid (solid lipid carrier) and oleic acid (liquid lipid content),
whereas, SLNs were prepared and optimised by using the solid lipid only. The particles were
characterised in terms of particle size analysis, thermal behaviour, morphology, stability and
in vitro release. The zeta sizer data revealed that the increase in the concentration of oleic
acid in the formulations reduced the mean particle size and the zeta potential. The increase in
concentration of oleic acid from 0 to 30% (w/w) resulted in a higher entrapment efﬁciency.
All nanoparticles were almost spherically shaped with an average particle size of about
∼170 nm. The DSC traces revealed that the presence of oleic acid in the NLC formulations
resulted in a shift in the melting endotherms to a higher temperature. This could be
attributed to a good long-term stability of the nanoparticles. The stability results showed that
the particle size remained smaller in NLC compared to that of SLN formulations after
6 months at various temperatures. The dissolution study showed about a 5.1- to 7.2-fold
increase in the release of the drug in 2 h compared to the raw drug. Comparing all
nanoparticle formulations indicated that the NLC composition with a ratio of 70:30
(solid:liquid lipid) is the most suitable formulation with desired drug dissolution rates,
entrapment efﬁciency and physical stability.
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INTRODUCTION
With the recent advent of high-throughput computa-
tional chemistry, the numbers of the poorly water-soluble or
insoluble lead compounds have signiﬁcantly risen.
Spironolactone (SP) falls into this group due to its very low
aqueous solubility and slow dissolution rate resulting in a
variable and poor oral bioavailability (1–6). SP has widely
been used over the last two decades to primarily treat edema,
hypertension and cutaneous disorders (e.g. acne, hirsutism
and androgenic alopecia) in the form of a tablet. Recent
studies revealed that about 40% of the drug candidates are
failing out the discovery pipeline due to their limited aqueous
solubility. Thus, the solubility enhancement of poorly water-
soluble SP is one of the key challenges in pharmaceutical
research (7). Various techniques have been reported to
increase the dissolution rate of poorly water-soluble SP, such
as cyclodextrin complexation approach, freeze-drying or
lyophilisation, solid dispersion strategy, liposomal formula-
tions and solid lipid nanoparticles (SLNs) approach (2–4,8).
Bourezg et al. prepared a SP-loaded SLN formulation and
reported as one of the efﬁcient ways to enhance the
dissolution of water-insoluble drugs (6). Moreover, lipid
nanoparticles (SLN and NLC) have the capability to enhance
the dissolution rate by overcoming the low and variable oral
bioavailability of various poorly water-soluble drugs (4,9).
The increase in the dissolution is mainly due to a signiﬁcant
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reduction in the drug particle size down to the nanorange
leading to the higher surface area available for dissolution. In
general, SLNs are produced using lipid carrier matrices that
are solid at both body and room temperatures. An optimised
combination of a solid lipid with a liquid lipid forms
nanoparticles with more internal defects known as NLC
(10). These lipid nanocarriers are produced by partially
interchanging the solid and liquid phases. One of the major
limitations of SLN approach is the low drug loading capacity.
Also, the drug leaking upon cooling and the possible negative
effects of polymorphic transformations of the lipid used in the
SLN are considered some drawbacks of the traditional SLN
approach (11). NLC can be used as an alternative efﬁcient
technique that contains the complex lipids and has a high
drug loading capacity compared to that of SLNs (11). In
addition to the high drug loads, this NLC can contain up to
95% solid (12,13).
Generally, most of NLC and SLN formulations are not
stable at high temperature or on storage. This instability can
modify the dissolution behaviour of particles due to aggrega-
tion leading to a poor dissolution. Therefore, in the present
work, attempts have been made to prepare the SP-loaded
SLNs and NLCs by means of a probe-ultrasonication method
to enhance the dissolution and stability of these
nanoformulations. For the purpose of this study, stearic acid
was used as a solid lipid while oleic acid as liquid lipid. To this
end, effects of oleic acid concentration on the particle size
were investigated and the physico-chemical properties of the
bulk SP and SP-loaded lipid nanoparticles were studied. To
explore more advantages for nanoformulations, their physical
stability during 6 months of storage at various temperatures
was also investigated.
MATERIALS AND METHODS
Materials
SP was generously provided by Behdashtkar Co.
(Pasdaran, Tehran, Iran). Compritol® 888 ATO, Lipocire
and Precirol® ATO 5 were supplied from Gattefossé (Saint-
Priest, Cedex, France). Stearic acid, oleic acid, Tween 80
(Tn80) and Span 80 (Sn80) were bought from Merck Co.
(Germany). HPLC-grade acetonitrile was supplied from
Merck Company. A Milli-Q system (Millipore, Direct-Q)
was used to purify the distilled water. All solvents were either
of analytical or high-performance liquid chromatography
(HPLC) grades and were used as received.
Lipid Screening
The solubility of SP was studied in different solid lipid
matrices with different proportion of oleic acid (0:100; 10:90;
20:80; 30:70) to select the most suitable lipid with a high
encapsulation efﬁciency. Four different solid lipid matrices,
namely Compritol® 888 ATO, Lipocire, Precirol® ATO 5
and stearic acid were used to determine the saturation
solubility of SP keeping the drug concentration constant at
25% w/w (only in this concentration, the saturated solution of
the drug can be obtained in the presence of stearic acid). For
solid lipid screening tests, certain amounts of SP were added
to the lipids and the mixtures were melted at 85°C under
stirring condition. The presence of drug crystals was visually
investigated to see which lipid is able to dissolve the added
drug crystals completely. Furthermore, the solubility of SP in
the molten solid lipid in combination with oleic acid as liquid
lipid (90:10, 80:20 and 70:30) was assessed. The lipid mixtures
were stirred using hot plate magnetic stirrer (Unimax 1010,
Heidolph, Germany) at 85°C and 200 rpm. The presence of
drug crystals in the molten lipid was visually assessed (see
Table I).
Preparation of SLN and NLC
Spironolactone-loaded SLNs (SP-SLN) and NLCs (SP-
NLCs) were manufactured and optimised via a process
utilising a probe ultrasonication. The method has been
adopted from the previously reported studies in literature
(6,14–16). To prepare SLNs and NLCs, a carrier lipid in its
solid form was melted at 85°C either alone or in combination
with liquid lipid (oleic acid) and Span 80. The drug was then
added and stirred until a complete dissolution was achieved.
The aqueous solution of Tn80 (Tween 80) was then added to
lipid phase under vigorous stirring using a high shear stress
homogeniser Ultra-Turrax® (IKA, Heidelberg, Germany) for
5 min at 10,000 rpm. Upon optimising the homogenous
mix tu re , t he hea t ed so lu t i on was then son i ca t ed
(Bandelinsonopuls, Berlin, Germany) for 5 min prior to
dispersing it into an ice-cold surfactant solution (Tn80).
When the solution was cooled to ambient temperature, a
further sonication for 10 min was applied to yield the lipid
nanoparticles. For more detail refer to Table II.
Particle Size and Zeta Potentials
A Zeta Sizer Nano ZS (Malvern Instruments, UK) was
used to measure the average particle size and zeta potential
of all SLNs and NLCs formulations at room temperature. All
samples were run in triplicate and the results shown in
Table II are the mean and SD values.
High-Performance Liquid Chromatography Analysis of SP
The drug content dissolved in the lipid nanoparticles
were determined by using a HPLC assay. The HPLC was
performed with an Agilent 1100 (Knauer, Berlin, Germany)
equipped with an XDB-C18 column from Agilent (5 μm,
Table I. Solid Lipid Screening for the Solubility Assessment of SP
Lipid 25 mg SP/100 mg solid:liquid lipid
100:00 90:10 80:20 70:30
Compritol® 888 ATO − − + +
Lipocire − − − −
Precirol® ATO 5 − − − −
Stearic acid + + + +
(+) indicates the drug is soluble in the phase, (−) indicates the drug is
not soluble in the phase
SP spironolactone
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4.6 mm × 250 mm). The mobile phase used was
acetonitrile:millipore water 70:30 (v/v). The UV wavelength
was set at 238 nm to detect the drug with a ﬂow rate of 0.8 ml/
min and the retention time of 7 min.
Determination of SP Entrapment Efficiency
To determine the SP entrapment efﬁciency (EE) in all
SLNs and NLCs prepared, the amount of free unloaded drug
was assessed by a centrifugation process. For this, SP-SLNs
and SP-NLCs were centrifuged by using a HERMLE, Z36HK
machine (Germany) for 20 min at 25,000 rpm, followed by a
ﬁltration with pore size 0.22 μm (n = 3). The drug content in
the supernatant was determined by HPLC method as
described above.
The EE of nanoparticles was calculated from Eq. (1).
EE ¼ Wi−Wf
Wi
 100 ð1Þ
Where, Wi and Wf are the initial drug amount and the
drug present in supernatant, respectively.
Morphology Measurement
A ﬁeld emission scanning electron microscope (FESEM,
HITACHI S-4160) was used to analyse the surface of the
prepared nanoparticles and the particle morphology. In order
to prepare the samples for analysis, a drop of suspension of
all formulations was placed on a double-sided carbon tape
followed by an overnight drying step at 25°C. Prior to
conducting the SEM study, the particles were subjected to a
sputter coating with gold for 40 s. The images were taken at
30 kV at a magniﬁcation of ×30,000.
DSC Measurement
The solid state of the raw drug, lipids, lyophilised SP-
SLNs and SP-NLCs were studied by a differential scanning
ca lor imetry (DSC 204 F1, Netzsch , Germany) .
Approximately, 3–12 mg of solid samples were accurately
weighed and placed into a standard aluminium pan and
sealed. All thermal transitions were recorded at a heating rate
of 10°C/min and all samples were heated from 30 and 220°C
under N2 atmosphere.
Stability Study of SLN and NLC
The physical stability of SP-loaded lipid nanoparticles
were studied at various temperatures (4, 25 and 40°C) for
6 months. Approximately 5 ml of nanoparticle suspension
were ﬁlled into glass vials and stored for 6 months. The
concentration of the nanoparticles was adjusted at 2 mg/ml.
At the end of the stability study period, the particle size
analysis was conducted to monitor the effect of the storage
condition on the solid lipid nanoparticles.
In Vitro Release Studies
In vitro dissolution studies were conducted by following
the protocol of the USP II (DH1520 dissolution apparatus,
ERWEKA, Germany). Lyophilized SP-SLNs and SP-NLCs
equivalent to 10 mg of SP were put into the vessels containing
900 ml of 0.1 M HCl solution at 37.0 ± 0.2°C with a paddle
rotation speed of 100 rpm. At different time intervals (20, 40,
60, 80, 120, 240 and 1440 min), the samples (1.5 ml) were
withdrawn from the dissolution vessels, centrifuged (20 min at
25,000 rpm) and ﬁltered (pore size 0.22 μm). The concentra-
tion of SP was determined using a HPLC method as
described above at 238 nm.
Statistical Analysis
The treated groups were compared with the reference
sample (control) by an analysis of variance (ANOVA),
following Dunnet’s test. The SPSS software was used to
perform all statistical analyses. The P value <0.05 was
considered as signiﬁcant. All the results are expressed as
mean ± standard deviation.
RESULTS AND DISCUSSION
A low drug payload, drug leakage on cooling etc. are
considered as some of the major challenges in the develop-
ment of SLNs. So, nowadays, an alternative to SLNs, an NLC
drug delivery system based on liquid lipid–solid lipid mixture
may solve the limitations associated with the conventional
SLNs. Unlike SLN, NLC contains the complex lipids. With
the presence of oil in these mixtures a melting point
depression compared to the pure solid lipid is observed in
NLC without compromising the solid state of the ﬁnal lipid
compositions (11,12). Typically, at low concentrations of oil
present in the NLC formulations, the oil molecules are
distributed within the solid lipid matrix. An adverse effect
can be observed when increasing the oil concentration due to
Table II. Formulation Composition and the Physico-chemical Characterization Data of the Prepared SP-Loaded SLN and NLC (% w/w)
Formula SP SA OA Sn80 Tn80 PS (nm) PI (nm) ZP (mV) EE (%)
SP-SLN 0.4 6.0 – 2.5 5 311.8 ± 19.0 0.199 ± 0.030 −13.6 ± 2.6 77.1 ± 2.6
SP-NLC1 0.4 5.4 0.6 2.5 5 288.0 ± 19.9 0.260 ± 0.050 −17.3 ± 1.8 84.7 ± 6.7
SP-NLC2 0.4 4.8 1.2 2.5 5 240.2 ± 49.3 0.203 ± 0.011 −22.1 ± 4.3 88.7 ± 4.2
SP-NLC3 0.4 4.2 1.8 2.5 5 146.4 ± 15.2 0.225 ± 0.012 −35.1 ± 3.0 90.6 ± 3.5
SP spironolactone, SA stearic acid, OA oleic acid, Sn80 Span 80, Tn80 Tween 80, PS particle size, PI polydispersity index, ZP zeta potential,
EE entrapment efﬁciency, SLN solid lipid nanoparticle, NLC nanostructured lipid carrier
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the phase separation resulting in the formation of an oily
nanocompartments are formed (13).
Therefore, the assessment of the most suitable lipid
carriers to prepare stable nanoparticles was optimised as the
ﬁrst step. As shown in Table I, various lipids with different
physical and chemical properties were selected. Unlike
other lipids, stearic acid performed better in terms of
producing a homogenous suspensions showing no drug
crystals upon heating with the drug. Therefore, stearic acid
was selected as the most suitable solid lipid to prepare
SLNs. All other lipids as shown in Table I failed to dissolve
SP completely.
It could be clearly observed from Table II that the
average particle size and zeta potential decreased with an
increase in the concentration of oleic acid (P > 0.05). These
results were in agreement with previously reported studies
(17). An increase in the liquid phase (oleic acid) in the
formulations reduced the viscosity of the NLC suspensions
and thus the surface tension and the particle size with
smoother surfaces (17). However, Yuan et al. indicated that
no obvious change in particle size was found when the oleic
acid content in NLC was further increased (18). In a separate
study, it has been reported that when oleic acid at concentra-
tions of 25 and 50% (w/w) was used no signiﬁcant changes
were observed on the average diameter and polydispersity
index of NLC (19). The phenomenon for zeta potential can
be explained by this fact that oleic acid has negative charge
because of its carboxylic groups. NLC3 revealed the highest
zeta potential values, possibly due to the accumulation of
oleic acid at the surface of the nanoparticles (19). It is evident
that the increased concentration of oleic acid resulted in the
increased drug entrapment efﬁciency (Table II) (P > 0.05). It
has been conﬁrmed that the presence of liquid phase in the
formulation provides enough space to accommodate the drug
particles in the porous network of the system leading to an
improved drug entrapment efﬁciency (17). The solubility of
the drug in the liquid lipid could probably be considered as
another key factor for the improved entrapment efﬁciency.
Particle morphology of the optimal formulation (SP-
NLC3) is shown in Fig. 1. The average particle size is about
150 nm (particle size range 110–175 nm) with almost spherical
shape and narrow size distribution. The SEM image showed
that some of the nanoparticles were aggregated which could
be due to the lipid nature of the carriers used in the presence
study. This aggregation could also be due to the sample
preparation prior to SEM analysis. Some of the particles in
Fig. 1 are departed from being complete spherical shape
which has also been reported for NLC (20).
Figure 2 shows the DSC thermal transitions of the raw
drug (SP), stearic acid, SP-SLN and the optimised SP-NLC3
formulations. The endothermic event shown at around
213.2°C corresponds to the melting point of pure
spironolactone (refer to Table III for more detail). In case
of SP-SLN and SP-NLC3, no endothermic peak was observed
in the melting range of SP (Fig. 3 and Table III). This could
be attributed to the entrapment of the drug within the lipid. It
could also be claimed that the drug may have been in the
amorphous form homogeneously dispersed in lipid matrices
(21). Pure stearic acid showed a sharp endothermic event
around 75°C corresponding to its melting endotherm. The
corresponding melting endotherms of each crystalline com-
ponents in the formulations shifted slightly at a lower
temperature (Table III). These differences are generally
ascribed to the nanometric size of the particles and also
partially could be due to the percentage of oleic acid in the
formulation. This is in a good agreement with published data
indicating a reduction in stearic acid melting point could be
related to the content of oleic acid in the formulations (17).
Figure 3 shows the particle size of two formulations (SP-
SLN and SP-NLC3) against storage time. The ﬁgure shows
that the storage temperature and the storage time played a
big role in the size growth of nanoparticles. For example,
when the storage time was increased from 3 to 6 months at
40°C, the size of SP-SLNs signiﬁcantly increased from around
400 to around 900 nm (P < 0.05). Similar trend was observed
Fig. 1. FESEM images of SP-NLC3 particles under high magniﬁcation
Fig. 2. DSC data of the stearic acid, SP and SP-loaded SLN and NLC3
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for SP-NLC3 formulations. Figure 3 also showed that within
the ﬁrst 3 months of the storage, no remarkable changes in
the size of particles was observed compared to the size of
nanoparticles immediately after the production. The ﬁgure
also showed that, although the size of nanoparticles after
6 months at 4 and 25°C was increased compared to the
samples stored for 3 months, this increase in the size was
signiﬁcantly smaller than the increase in the size of nanopar-
ticles at 40°C after 6 months. This data indicated that the
nanoparticles are more stable at 4 or 25°C compared to the
samples stored at 40°C. This can be supported by zeta
potential data reported in Fig. 4. This ﬁgure showed that in
the case of SLN formulations when the particles stored at
different temperatures (4, 25 and 40°C) a signiﬁcant reduction
(P < 0.05) in zeta potential was only observed for the samples
stored at 40°C for 3 and 6 months which could be due to the
aggregation of particles at 40°C. It seems that these nanopar-
ticles are more stable at lower temperatures. Similar results
were obtained for NLC3 formulation.
These results are reﬂection of long-term stability of the
nanoparticles at 4 and 25°C. This observation was conﬁrmed
by the assessment of the particle size homogeneity and
absence of any phase separation (22). Jenning et al. had used
the wide-angle X-ray diffraction to study the polymorphic
transitions of SLN made from stearic acid in oil/water cream
(23). They found that after 6 months, SLNs still remained in
the nanoparticulate state. The good stability might derive
from the slow transition of lipid in SLN and NLC and the
steric effect of surfactant (24).
Dissolution proﬁle of freeze-dried SP-SLN, SP-NLC3
and raw drug were presented in Fig. 5. The accelerated
dissolution for SP-SLN and SP-NLC3 could be mainly
ascribed to the reduced particle size providing a greater
surface area compared to the particle size of raw drug. The
SLN and NLC powder showed burst release in the early stage
of dissolution compared to raw SP. This could be due to the
diffusion of un-encapsulated drug from the particles surface
followed by the diffusion from the core. The homogenously
distributed oleic acid in nanoparticles may have been another
explanation for steady release followed by burst release of
NLC formulations. Hu et al. showed that the release rate at
the initial stage increased with the increasing oleic acid
content in nanoparticles and this phenomenon is dependent
on homogeneity of liquid lipid in solid lipid during the NLC
preparation (17).
Obviously, at the initial stage, the drug release was
slower in SLN compared to NLC and after that, the release
proﬁles of SLN and NLC were almost parallel and their
slopes tended to be similar. The faster drug release from NLC
compared to SLN could be due to the presence of liquid lipid
in the structure of NLC (25).
In conclusion, both NLC and SLN present a solid lipid
matrix, but NLCs are prepared with a mixture of solid lipid
and liquid lipid (oil) which increased the drug loading and
stability compared to SLN formulations. This also could be
due to the creation of a less ordered lipid matrix, by mixing
solid lipid and liquid lipid. The major advantage of SLN is the
Table III. DSC Thermal Events of the Bulk Materials and the
Formulations
Formula OA (%) Onset (°C) Melting
point (°C)
Enthalpy
(J/g)
Spironolactone – 209.44 213.24 386.77
Stearic acid – 69.90 75.25 255.71
SP-SLN 0 52.97 62.55 76.11
SP-NLC1 10 50.94 61.59 60.02
SP-NLC2 20 48.95 59.23 52.86
SP-NLC3 30 44.76 57.10 46.33
SP spironolactone, OA oleic acid, SLN solid lipid nanoparticle, NLC
nanostructured lipid carrier
Fig. 3. Particle size of SP-SLN and SP-NLC3 formulations after
production, 3 and 6 months of storage at 4, 25 and 40°C
Fig. 4. Zeta potential of different formulations at different storage
conditions
Fig. 5. Comparison of dissolution proﬁles of freeze-dried SP-SLN
and SP-NLC3 compared to raw SP
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possibility of production on large industrial scale. However,
depending on the drug some potential problems can occur,
such as drug leakage during storage and insufﬁcient total drug
load. Despite these statements, controversial results have
been found in the literature about the differences between
SLN and NLC (26). Comparing all nanoparticle formulations
indicated that in the present study, the SP-NLCs are better
than SP-SLNs in terms of dissolution rates, entrapment
efﬁciency and physical stability.
CONCLUSIONS
It can be concluded that with increasing the proportion
of oleic acid in NLC, the average size and zeta potential of
nanoparticles decreased signiﬁcantly. Similarly, the EE in-
creased dramatically due to the presence of interstitial spaces
to accommodate the drug particles in the systems. The
stability results showed that the particle size remained smaller
in NLC compared to that of SLN formulations even after
6 months. The in vitro dissolution study showed about a 5.1-
and 7.2-fold increase in the release of the drug in 2 h
compared to the raw drug. The effect of stabiliser on
preventing aggregation of nanoparticles, both in the SLN
and NLC in terms of achieving even longer-term stability can
be assessed in the future.
ACKNOWLEDGMENTS
This work was partially supported by the Mazandaran
University of Medical Sciences. The authors would like to
thank Mrs. Choupani, Mrs. Rezanejad, Mr. Eslami and Mr.
Farmoudeh for their assistance.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License
(http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original
author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made.
REFERENCES
1. Kocbek P, Baumgartner S, Kristl J. Preparation and evaluation
of nanosuspensions for enhancing the dissolution of poorly
soluble drugs. Int J Pharm. 2006;312:179–86.
2. Dong Y, Ng WK, Shen S, Kim S, Tan RBH. Preparation and
characterization of spironolactone nanoparticles by antisolvent
precipitation. Int J Pharm. 2009;375:84–8.
3. Dong Y, Ng WK, Shen S, Kim S, Tan RBH. Controlled
antisolvent precipitation of spironolactone nanoparticles by
impingement mixing. Int J Pharm. 2011;410:175–9.
4. Dong Y, Ng WK, Hu J, Shen S, Tan RBH. A continuous and
highly effective static mixing process for antisolvent precipitation
of nanoparticles of poorly water-soluble drugs. Int J Pharm.
2010;386:256–61.
5. Laouini A, Jaafar-Maalej C, Sfar S, Charcosset C, Fessi H. Liposome
preparation using a hollow ﬁbermembrane contactor—application to
spironolactone encapsulation. Int J Pharm. 2011;415:53–61.
6. Bourezg Z, Bourgeois S, Pressenda S, Shehada T, Fessi H.
Redispersible lipid nanoparticles of spironolactone obtained by
three drying methods. Colloids Surf Physicochem Eng Aspects.
2012;413:191–9.
7. Ohshima H, Miyagishima A, Kurita T, Makino Y, Iwao Y,
Sonobe T, et al. Freeze-dried nifedipine-lipid nanoparticles with
long-term nano-dispersion stability after reconstitution. Int J
Pharm. 2009;377:180–4.
8. Kelidari HR, Saeedi M, Akbari J, Morteza-Semnani K, Gill P,
Valizadeh H, et al. Formulation optimization and in vitro skin
penetration of spironolactone loaded solid lipid nanoparticles.
Colloids Surf B: Biointerfaces. 2015;128:473–9.
9. Patil-Gadhe A, Pokharkar V. Montelukast-loaded nanostruc-
tured lipid carriers: part I. Oral bioavailability improvement. Eur
J Pharm Biopharm. 2014;88:160–8.
10. Aditya NP, Macedo AS, Doktorovova S, Souto EB, Kim S,
Chang P-S, et al. Development and evaluation of lipid
nanocarriers for quercetin delivery: a comparative study of solid
lipid nanoparticles (SLN), nanostructured lipid carriers (NLC),
and lipid nanoemulsions (LNE). LWT Food Sci Technol.
2014;59:115–21.
11. Kumar S, Randhawa JK. High melting lipid based approach for
drug delivery: solid lipid nanoparticles. Mater Sci. 2013;33:
1842–52.
12. Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN,
NLC) in cosmetic and pharmaceutical dermal products. Int J
Pharm. 2009;366:170–84.
13. Müller R, Radtke M, Wissing S. Solid lipid nanoparticles (SLN)
and nanostructured lipid carriers (NLC) in cosmetic and
dermatological preparations. Adv Drug Deliv Rev.
2002;54:131–55.
14. Shah RM, Malherbe F, Eldridge D, Palombo EA, Harding IH.
Physicochemical characterization of solid lipid nanoparticles
(SLNs) prepared by a novel microemulsion technique. Colloids
Surf B: Biointerfaces. 2014;428:286–94.
15. Puglia C, Blasi P, Rizza L, Schoubben A, Bonina F, Rossi C, et al.
Lipid nanoparticles for prolonged topical delivery: an in vitro
and in vivo investigation. Int J Pharm. 2008;357:295–304.
16. Gonzalez-Mira E, Egea MA, Garcia ML, Souto EB. Design and
ocular tolerance of ﬂurbiprofen loaded ultrasound-engineered
NLC. Colloids Surf B: Biointerfaces. 2010;81:412–21.
17. Hu F-Q, Jiang S-P, Du Y-Z, Yuan H, Ye Y-Q, Zeng S.
Preparation and characterization of stearic acid nanostructured
lipid carriers by solvent diffusion method in an aqueous system.
Colloids Surf B: Biointerfaces. 2005;45:167–73.
18. Yuan H, Wang L-L, Du Y-Z, You J, Hu F-Q, Zeng S.
Preparation and characteristics of nanostructured lipid carriers
for control-releasing progesterone by melt-emulsiﬁcation.
Colloids Surf B: Biointerfaces. 2007;60:174–9.
19. Souza LG, Silva EJ, Martins ALL, Mota MF, Braga RC, Lima
EM, et al. Development of topotecan loaded lipid nanoparticles
for chemical stabilization and prolonged release. Eur J Pharm
Biopharm. 2011;79:189–96.
20. Marquele-Oliveira F, Santana DC, Taveira SF, Vermeulen DM,
de Oliveira AR, da Silva RS, et al. Development of nitrosyl
ruthenium complex-loaded lipid carriers for topical administra-
tion: improvement in skin stability and in nitric oxide release by
visible light irradiation. J Pharm Biomed Anal. 2010;53:843–51.
21. Uprit S, Kumar Sahu R, Roy A, Pare A. Preparation and
characterization of minoxidil loaded nanostructured lipid carrier
gel for effective treatment of alopecia. Saudi Pharm J.
2013;21:379–85.
22. Ali H, Shirode AB, Sylvester PW, Nazzal S. Preparation and
in vitro antiproliferative effect of tocotrienol loaded lipid
nanoparticles. Colloids Surf Physicochem Eng Aspects.
2010;353:43–51.
23. Jenning V, Thünemann AF, Gohla SH. Characterisation of a
novel solid lipid nanoparticle carrier system based on binary
mixtures of liquid and solid lipids. Int J Pharm. 2000;199:167–77.
24. Venkateswarlu V, Manjunath K. Preparation, characterization
and in vitro release kinetics of clozapine solid lipid nanoparticles.
J Control Release. 2004;95:627–38.
25. Souto EB, Wissing SA, Barbosa CM, Müller RH. Development
of a controlled release formulation based on SLN and NLC for
topical clotrimazole delivery. Int J Pharm. 2004;278:71–7.
26. Andrade LM, de Fátima RC, Maione-Silva L, Anjos JL, Alonso
A, Serpa RC, et al. Impact of lipid dynamic behavior on physical
stability, in vitro release and skin permeation of genistein-loaded
lipid nanoparticles. Eur J Pharm Biopharm. 2014;88:40–7.
Kelidari et al.
